These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 37626170)

  • 1. RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts.
    Watts GF; Schwabe C; Scott R; Gladding PA; Sullivan D; Baker J; Clifton P; Hamilton J; Given B; Melquist S; Zhou R; Chang T; San Martin J; Gaudet D; Goldberg IJ; Knowles JW; Hegele RA; Ballantyne CM
    Nat Med; 2023 Sep; 29(9):2216-2223. PubMed ID: 37626170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Updates in Small Interfering RNA for the Treatment of Dyslipidemias.
    Carugo S; Sirtori CR; Gelpi G; Corsini A; Tokgozoglu L; Ruscica M
    Curr Atheroscler Rep; 2023 Nov; 25(11):805-817. PubMed ID: 37792132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNA Interference Therapy Targeting Apolipoprotein C-III in Hypertriglyceridemia.
    Gaudet D; Clifton P; Sullivan D; Baker J; Schwabe C; Thackwray S; Scott R; Hamilton J; Given B; Melquist S; Zhou R; Chang T; San Martin J; Watts GF; Goldberg IJ; Knowles JW; Hegele RA; Ballantyne CM
    NEJM Evid; 2023 Dec; 2(12):EVIDoa2200325. PubMed ID: 38320498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets.
    Akoumianakis I; Zvintzou E; Kypreos K; Filippatos TD
    Curr Atheroscler Rep; 2021 Mar; 23(5):20. PubMed ID: 33694000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides.
    Graham MJ; Lee RG; Brandt TA; Tai LJ; Fu W; Peralta R; Yu R; Hurh E; Paz E; McEvoy BW; Baker BF; Pham NC; Digenio A; Hughes SG; Geary RS; Witztum JL; Crooke RM; Tsimikas S
    N Engl J Med; 2017 Jul; 377(3):222-232. PubMed ID: 28538111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic inhibition of angiopoietin-like protein-3, lipids, and cardiometabolic risk.
    Gobeil É; Bourgault J; Mitchell PL; Houessou U; Gagnon E; Girard A; Paulin A; Manikpurage HD; Côté V; Couture C; Marceau S; Bossé Y; Thériault S; Mathieu P; Vohl MC; Tchernof A; Arsenault BJ
    Eur Heart J; 2024 Mar; 45(9):707-721. PubMed ID: 38243829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70.
    Bergmark BA; Marston NA; Bramson CR; Curto M; Ramos V; Jevne A; Kuder JF; Park JG; Murphy SA; Verma S; Wojakowski W; Terra SG; Sabatine MS; Wiviott SD;
    Circulation; 2022 May; 145(18):1377-1386. PubMed ID: 35369705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ANGPTL3 as a Drug Target in Hyperlipidemia and Atherosclerosis.
    Mohamed F; Mansfield BS; Raal FJ
    Curr Atheroscler Rep; 2022 Dec; 24(12):959-967. PubMed ID: 36367663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reductions in remnant cholesterol and VLDL cholesterol through inhibition of ANGPTL3 protein synthesis: an analysis from the TRANSLATE-TIMI 70 trial.
    Zimerman A; Wiviott SD; Park JG; Murphy SA; Ran X; Bramson CR; Curto M; Ramos V; Jevne A; Kuder JF; Verma S; Wojakowski W; Terra SG; Sabatine MS; Bergmark BA; Marston NA
    Eur J Prev Cardiol; 2024 Mar; ():. PubMed ID: 38484368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ANGPTL3 Deficiency and Risk of Hepatic Steatosis.
    D'Erasmo L; Di Martino M; Neufeld T; Fraum TJ; Kang CJ; Burks KH; Di Costanzo A; Minicocci I; Bini S; Maranghi M; Pigna G; Labbadia G; Zheng J; Fierro D; Montali A; Ceci F; Catalano C; Davidson NO; Lucisano G; Nicolucci A; Arca M; Stitziel NO
    Circulation; 2023 Nov; 148(19):1479-1489. PubMed ID: 37712257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Randomized, Open-Label, Phase I, Single-Dose Study of Antisense Oligonucleotide, Vupanorsen, in Chinese Adults with Elevated Triglycerides.
    Wu X; Yu J; Ge B; Wang J; Han X; Zhang C; Mao X; Kalluru H; Bramson C; Terra SG; Liu J
    Drugs R D; 2024 Jul; ():. PubMed ID: 38949758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease.
    Dewey FE; Gusarova V; Dunbar RL; O'Dushlaine C; Schurmann C; Gottesman O; McCarthy S; Van Hout CV; Bruse S; Dansky HM; Leader JB; Murray MF; Ritchie MD; Kirchner HL; Habegger L; Lopez A; Penn J; Zhao A; Shao W; Stahl N; Murphy AJ; Hamon S; Bouzelmat A; Zhang R; Shumel B; Pordy R; Gipe D; Herman GA; Sheu WHH; Lee IT; Liang KW; Guo X; Rotter JI; Chen YI; Kraus WE; Shah SH; Damrauer S; Small A; Rader DJ; Wulff AB; Nordestgaard BG; Tybjærg-Hansen A; van den Hoek AM; Princen HMG; Ledbetter DH; Carey DJ; Overton JD; Reid JG; Sasiela WJ; Banerjee P; Shuldiner AR; Borecki IB; Teslovich TM; Yancopoulos GD; Mellis SJ; Gromada J; Baras A
    N Engl J Med; 2017 Jul; 377(3):211-221. PubMed ID: 28538136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ANGPTL3 as therapeutic target.
    Kersten S
    Curr Opin Lipidol; 2021 Dec; 32(6):335-341. PubMed ID: 34581310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: New therapeutic approaches for the treatment of atherogenic dyslipidemia.
    Ruscica M; Zimetti F; Adorni MP; Sirtori CR; Lupo MG; Ferri N
    Pharmacol Res; 2020 Mar; 153():104653. PubMed ID: 31931117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of angiopoietin-like 3 for the management of severe hypercholesterolemia.
    Mohamed F; Botha TC; Raal FJ
    Curr Opin Lipidol; 2021 Aug; 32(4):213-218. PubMed ID: 33883446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia.
    Rosenson RS; Gaudet D; Hegele RA; Ballantyne CM; Nicholls SJ; Lucas KJ; San Martin J; Zhou R; Muhsin M; Chang T; Hellawell J; Watts GF;
    N Engl J Med; 2024 May; ():. PubMed ID: 38809174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia.
    Ahmad Z; Banerjee P; Hamon S; Chan KC; Bouzelmat A; Sasiela WJ; Pordy R; Mellis S; Dansky H; Gipe DA; Dunbar RL
    Circulation; 2019 Aug; 140(6):470-486. PubMed ID: 31242752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis.
    Mak LY; Gane E; Schwabe C; Yoon KT; Heo J; Scott R; Lee JH; Lee JI; Kweon YO; Weltman M; Harrison SA; Neuschwander-Tetri BA; Cusi K; Loomba R; Given BD; Christianson DR; Garcia-Medel E; Yi M; Hamilton J; Yuen MF
    J Hepatol; 2023 Apr; 78(4):684-692. PubMed ID: 36513186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol.
    Xu YX; Redon V; Yu H; Querbes W; Pirruccello J; Liebow A; Deik A; Trindade K; Wang X; Musunuru K; Clish CB; Cowan C; Fizgerald K; Rader D; Kathiresan S
    Atherosclerosis; 2018 Jan; 268():196-206. PubMed ID: 29183623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in Dyslipidaemia Treatments: Focusing on ApoC3 and ANGPTL3 Inhibitors.
    Tomlinson B; Wu QY; Zhong YM; Li YH
    J Lipid Atheroscler; 2024 Jan; 13(1):2-20. PubMed ID: 38299167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.